Compare ADMA Biologics Inc (ADMA) vs Xylem, Inc. (XYL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Xylem, Inc. — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while Xylem, Inc. trades at $118.39 (market cap $28.68B). The key difference: Xylem, Inc. is far larger — about 13.5× ADMA Biologics Inc's market cap, and Xylem, Inc. pays a 1.43% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | XYL | |
|---|---|---|
Market Cap | $2.13B | $28.68B |
Sector | Health | Industrials |
52-Week High | $20.38 | $152.95 |
52-Week Low | $7.60 | $106.34 |
Enterprise Value | $2.20B | $29.93B |
Dividend Yield | — | 1.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Xylem (XYL) trades at $120.65, up 2.14% today, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. Revenue grew to $9.04B in 2025, with net income margin improving to 10.79%. Recent news highlights strategic partnerships and leadership appointments, reinforcing its position in water technology solutions.
The stock offers upside to the $153.14 consensus price target, driven by steady earnings growth and margin expansion. Risks include execution challenges in a competitive market and potential macroeconomic headwinds affecting industrial demand. Analyst sentiment is mixed but leans positive with 47.5% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
